Why don't you decide if this is the next Humera? You can decide the market size of the HIV, Cancer, NASH and GvHD markets and com up with a number and decide if/how much Leronlimab will be in those markets. Why is it important to judge Nader on this? I invested in a company with a product that is quite impressive - I did not invest in a company because of Nader. This is not against Nader, but Nader is in this company for the drug also, not because of himself either. Nader uses Humera as an example because he did the same math and came up with a supportable comparison.

PS - this sounds harsher than I intend - just making a point.